Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Gopalakrishnan S, Menon R, Suleiman AA, Kater AP, Stilgenbauer S, Seymour JF, Chyla B, Lu T, Young Kim S, Roberts AW, Woyach JA, Mensing S, Salem AH. Gopalakrishnan S, et al. Among authors: roberts aw. Hemasphere. 2023 Nov 17;7(12):e983. doi: 10.1097/HS9.0000000000000983. eCollection 2023 Dec. Hemasphere. 2023. PMID: 38026788 Free PMC article. No abstract available.
Statins enhance efficacy of venetoclax in blood cancers.
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Lee JS, et al. Sci Transl Med. 2018 Jun 13;10(445):eaaq1240. doi: 10.1126/scitranslmed.aaq1240. Sci Transl Med. 2018. PMID: 29899021 Free PMC article.
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Juarez D, Buono R, Matulis SM, Gupta VA, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh SM, Dong VM, Roberts AW, Leverson JD, Jalaluddin M, Liu Z, Bueno OF, Boise LH, Fruman DA. Juarez D, et al. Among authors: roberts aw. Cancer Res Commun. 2023 Dec 8;3(12):2497-2509. doi: 10.1158/2767-9764.CRC-23-0350. Cancer Res Commun. 2023. PMID: 37956312 Free PMC article.
Sensitivity of canine hematological cancers to BH3 mimetics.
Jegatheeson S, Cannon C, Mansfield C, Devlin J, Roberts A. Jegatheeson S, et al. J Vet Intern Med. 2023 Jan;37(1):236-246. doi: 10.1111/jvim.16587. Epub 2022 Nov 25. J Vet Intern Med. 2023. PMID: 36433867 Free PMC article.
Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
Luo MX, Tan T, Trussart M, Poch A, Nguyen MT, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CSL, Lindeman GJ, Huang DCS Professor, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DHD. Luo MX, et al. Among authors: roberts aw. Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341. Online ahead of print. Blood. 2024. PMID: 39471335
Corrigendum to Indicated vs universal third-trimester ultrasound examination in low-risk pregnancies: a pre-post-intervention study [American Journal of Obstetrics & Gynecology MFM Volume 6, Issue 5, May 2024, 101373].
Roberts AW, Hotra J, Soto E, Pedroza C, Sibai BM, Blackwell SC, Chauhan SP. Roberts AW, et al. Am J Obstet Gynecol MFM. 2024 Jul;6(7):101389. doi: 10.1016/j.ajogmf.2024.101389. Epub 2024 Jun 5. Am J Obstet Gynecol MFM. 2024. PMID: 38845249 No abstract available.
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Diepstraten ST, et al. Among authors: roberts aw. Cancer Cell. 2024 May 13;42(5):850-868.e9. doi: 10.1016/j.ccell.2024.04.004. Epub 2024 Apr 25. Cancer Cell. 2024. PMID: 38670091 Free article.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, Di Iulio J, Hicks RJ, Westerman D, Lade S, Pott C, Agarwal R, Koldej R, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: roberts aw. Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388. Blood. 2024. PMID: 38662991 Free PMC article. Clinical Trial.
338 results